Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir.

The article presents a study on the hepatotoxicity and gastrointestinal intolerance of healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. The study primarily evaluates the pharmoacokinetic interactions and safety of atazanavir, ritonavir and rifampin among HIV-seronegative volunteers. Results are included, concluding that the co-administration of rifampin with HIV protease inhibitors may not be a viable treatment option for protease inhibitor irritation.